<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>
Adolescence is characterised by a substantial increase in the incidence of tuberculosis, a known fact since the early 20th century. Most of the world's adolescents live in low-income and middle-income countries where tuberculosis remains common, and where they comprise a quarter of the population. Despite this, adolescents have not yet been addressed as a distinct population in tuberculosis policy or within tuberculosis treatment services, and emerging evidence suggests that current models of care do not meet their needs. This Review discusses up-to-date information about tuberculosis in adolescence, with a focus on the management of infection and disease, including HIV co-infection and rifampicin-resistant tuberculosis. We outline the progress in vaccine development and highlight important directions for future research.
Adolescent, PULMONARY TUBERCULOSIS, Antitubercular Agents, 610, XPERT MTB/RIF ASSAY, CHILDREN, HIV Infections, Pediatrics, Young Adult, ANTIRETROVIRAL THERAPY, 616, YOUNG-ADULTS, INFECTION, Tuberculosis, Multidrug-Resistant, CHILDHOOD TUBERCULOSIS, Humans, Tuberculosis, MULTIDRUG-RESISTANT TUBERCULOSIS, Child, Tuberculosis Vaccines, Developing Countries, Science & Technology, Coinfection, Incidence, Multidrug-Resistant, HEALTH-CARE, MYCOBACTERIUM-TUBERCULOSIS, TREATMENT OUTCOMES, Life Sciences & Biomedicine
Adolescent, PULMONARY TUBERCULOSIS, Antitubercular Agents, 610, XPERT MTB/RIF ASSAY, CHILDREN, HIV Infections, Pediatrics, Young Adult, ANTIRETROVIRAL THERAPY, 616, YOUNG-ADULTS, INFECTION, Tuberculosis, Multidrug-Resistant, CHILDHOOD TUBERCULOSIS, Humans, Tuberculosis, MULTIDRUG-RESISTANT TUBERCULOSIS, Child, Tuberculosis Vaccines, Developing Countries, Science & Technology, Coinfection, Incidence, Multidrug-Resistant, HEALTH-CARE, MYCOBACTERIUM-TUBERCULOSIS, TREATMENT OUTCOMES, Life Sciences & Biomedicine
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 93 | |
popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 1% | |
influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 1% |